Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 6/20 | 0.45 |
| ▸ | AKR1C2 | P52895 | 6/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 4/20 | 0.44 |
| ▸ | GFER | P55789 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | THRB | P10828 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | PRKCI | P41743 | 1/20 | 0.43 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.41 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.41 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.41 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.41 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27697339 | 0.84 | ROCK1 (0.40) | NPC1SMN1; SMN2POLBRAB9AGAA | |
| SCHEMBL2652297 | 0.84 | MAPT (0.48) | AKR1C3AKR1C2NPC1SMN1; SMN2POLB | |
| SCHEMBL2650071 | 0.82 | GAA (0.49) | AKR1C3AKR1C2NPC1SMN1; SMN2GAA | |
| SCHEMBL27697342 | 0.80 | ROCK1 (0.36) | NPC1SMN1; SMN2POLBRAB9AGAA | |
| SCHEMBL2647667 | 0.79 | GAA (0.48) | AKR1C3AKR1C2NPC1SMN1; SMN2RAB9A | |
| SCHEMBL2643439 | 0.78 | NPC1 (0.53) | AKR1C3AKR1C2NPC1RAB9AGAA | |
| SCHEMBL2648414 | 0.77 | CNR1 (0.49) | AKR1C3AKR1C2NPC1SMN1; SMN2POLB | |
| SCHEMBL9071956 | 0.74 | AKR1C3 (0.69) | AKR1C3AKR1C2NPC1SMN1; SMN2GAA | |
| SCHEMBL2655100 | 0.74 | GAA (0.46) | AKR1C3AKR1C2NPC1SMN1; SMN2GAA | |
| SCHEMBL7989959 | 0.73 | GAA (0.77) | AKR1C3AKR1C2NPC1SMN1; SMN2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7851490-B2 | Benzimidazole derivatives and their use for modulating the GABAA receptor complex | NEUROSEARCH A/S (DK) | 2010-12-14 | — | — | US | disclosed |
| EP-1877052-B1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | NEUROSEARCH AS (DK) | 2009-07-22 | — | — | EP | disclosed |
| US-20090036493-A1 | Benzimidazole Derivatives and Their Use for Modulating the GABA Alpha Receptor Complex | ANIONA APS (DK) | 2009-02-05 | — | — | US | disclosed |
| EP-1877052-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | NEUROSEARCH A/S (DK) | 2008-01-16 | — | — | EP | disclosed |
| WO-2006108800-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | NEUROSEARCH A/S (DK) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036493-A1 | Benzimidazole Derivatives and Their Use for Modulating the GABA Alpha Receptor Complex | GABRB2, GABRB1, GABRB3 | AKR1C3 947/4885AKR1C2 906/4885NPC1 1618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.